Results 21 to 30 of about 5,711,116 (385)

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.

open access: yesThe Journal of the National Comprehensive Cancer Network, 2021
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease.
E. Schaeffer   +31 more
semanticscholar   +1 more source

Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea

open access: yesBMC Cancer, 2018
Background For the expanding population of bladder cancer survivors in Korea, the development of subsequent cancers is a significant concern. Here, we provide the second primary cancer incidence rates and types in Korean patients with bladder cancer ...
Whi-An Kwon   +10 more
doaj   +1 more source

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

open access: yesNew England Journal of Medicine, 2004
BACKGROUND Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival.
I. Tannock   +11 more
semanticscholar   +1 more source

Cancer statistics, 2022

open access: yesCa, 2022
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population‐based cancer occurrence and outcomes.
R. Siegel   +3 more
semanticscholar   +1 more source

Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

open access: yesBMC Cancer, 2018
Background Bleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs).
Nicola J. Lawrence   +16 more
doaj   +1 more source

Lifetime risk of prostate cancer overdiagnosis in Australia: Quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach [PDF]

open access: yes, 2019
© 2019 Author(s). Objectives To quantify the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.
Bell, Katy   +4 more
core   +3 more sources

Increased survival with enzalutamide in prostate cancer after chemotherapy.

open access: yesNew England Journal of Medicine, 2012
BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth.
H. Scher   +19 more
semanticscholar   +1 more source

Components of cell-matrix linkage as potential new markers for prostate cancer [PDF]

open access: yes, 2011
Prostate cancer is one of the most common tumor diseases worldwide. Often being non-aggressive, prostate tumors in these cases do not need immediate treatment.
Eble, Johannes Andreas, Navdaev, Alexey
core   +2 more sources

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma

open access: yesGenome Medicine, 2019
Background Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or chemotherapy, and no effective targeted ...
Raunak Shrestha   +32 more
doaj   +1 more source

The molecular basis for ethnic variation and histological subtype differences in prostate cancer. [PDF]

open access: yes, 2013
Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity and mortality of prostate cancer increase dramatically in several oriental countries including China.
Goldstein, Andrew S   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy